

Shield Therapeutics plc
("Shield" or the "Group" or the "Company")

Results of 2020 Annual General Meeting

London, UK, 18 June 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2020. The Board reports that resolutions 1 to 8 passed as ordinary resolutions and resolutions 9 and 10 were passed as special resolutions, full details are shown below.

The following table shows the votes cast on each resolution:

	VOTES FOR	%	VOTES AGAINST	%	VOTES TOTAL	VOTES WITHELD
1	80,464,174	99.05	769,230	0.95	81,233,404	0
2	80,464,174	99.05	769,230	0.95	81,233,404	0
3	81,233,404	100	0	0	81,233,404	0
4	80,464,174	99.05	769,230	0.95	81,233,404	0
5	80,464,174	100	0	0	81,233,404	769,230
6	80,461,731	99.05	771,673	0.95	81,233,404	0
7	81,233,372	99.99	32	0.01	81,233,404	0
8	80,461,763	99.99	2,411	0.01	81,233,404	769,230
9	81,230,993	99.99	2,411	0.01	81,233,404	0
10	80,461,763	99.05	771,641	0.95	81,233,404	0

Notes:

1. Percentage of shares voted: 69% (number of shares in issue 117,188,657).
2. Details of the votes received on the resolutions are available on the Company's website: <https://www.shieldtherapeutics.com/corporate-documents/>.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

For further information please contact:

Shield Therapeutics plc

Tim Watts, CEO
Lucy Bailey, Company Secretary and General Counsel

www.shieldtherapeutics.com

+44 (0)20 7186 8500
+44 (0)19 1511 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/Matt Radley/Alice Lane

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Paul McManus/Lianne Cawthorne

+44 (0)20 7933 8780 or shield@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru[®]/ Accrufer[®] has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru[®] with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer[®] with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru[®]/Accrufer[®] in China, Hong Kong, Macau and Taiwan. For more information please visit www.shieldtherapeutics.com

About Feraccru[®]/Accrufer[®]

Feraccru[®]/Accrufer[®] is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, and offers a compelling alternative to IV iron for those patients unable to tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.

When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru[®]/Accrufer[®] is not an iron salt and, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies, whilst the iron from the ferric maltol molecule can be readily absorbed.

Prior to Feraccru[®]/Accrufer[®], IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru[®]/Accrufer[®] meets those requirements.

About Iron Deficiency

The WHO states that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of women and children in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialised nations. There are no current global figures for iron deficiency but, using anaemia as an indirect indicator, it can be estimated that most preschool children and pregnant women in non-industrialised countries, together with at least 30-40% in industrialized countries, are iron deficient.